Aaron J. Cantor

Aaron J. Cantor

Auto-generated profile, based on publicly available information

Aaron J. Cantor

Affiliation Spotlight Therapeutics, Hayward, CA, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2009 in Cell
Verified
Journal Article
Closed access
KSKyle R. Simonetta
Kyle R. Simonetta
SKSteven L. Kazmirski
Steven L. Kazmirski
EGEric R. Goedken
Eric R. Goedken
ACAaron J. Cantor
Aaron J. Cantor
BKBrian A. Kelch
Brian A. Kelch
JKJohn Kuriyan
John Kuriyan

1 August 2020 in Cell Reports
Verified
Journal Article
Open access
MBMatthew Bratkowski
Matthew Bratkowski
TXTian Xie
Tian Xie
DTDesiree A. Thayer
Desiree A. Thayer
SLShradha Lad
Shradha Lad
PMPrakhyat Mathur
Prakhyat Mathur
SSShilpa Sambashivan
Shilpa Sambashivan
The NADase SARM1 is a central switch in injury-activated axon degeneration, an early hallmark of many neurological diseases. Here, we present cryo-electron microscopy (cryo-EM) structures of autoinhibited (3.3 Å) and active SARM1 (6.8 Å) and provide mechanistic insight into the tight regulation of SARM1's function by the local metabolic environment. Although both states retain an octameric core, the defining feature of the autoinhibited state is a lock between the autoinhibitory Armadillo/HEAT motif (ARM) and catalytic Toll/interleukin-1 receptor (TIR) domains, which traps SARM1 in an inactive state. Mutations that break this lock activate SARM1, resulting in catastrophic neuronal death. Notably, the mutants cannot be further activated by the endogenous activator nicotinamide mononucleotide (NMN), and active SARM1 is product inhibited by Nicotinamide (NAM), highlighting SARM1's functional dependence on key metabolites in the NAD salvage pathway. Our studies provide a molecular understanding of SARM1's transition from an autoinhibited to an injury-activated state and lay the foundation for future SARM1-based therapies to treat axonopathies.

1 October 2014 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
NENicholas F. Endres
Nicholas F. Endres
TBTiago Barros
Tiago Barros
ACAaron J. Cantor
Aaron J. Cantor
JKJohn Kuriyan
John Kuriyan

1 September 2015 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
EKErika Kovacs
Erika Kovacs
RDRahul Das
Rahul Das
QWQi Wang
Qi Wang
TCTimothy S. Collier
Timothy S. Collier
ACAaron Cantor
Aaron Cantor
JKJohn Kuriyan
John Kuriyan
The ∼230-residue C-terminal tail of the epidermal growth factor receptor (EGFR) is phosphorylated upon activation. We examined whether this phosphorylation is affected by deletions within the tail and whether the two tails in the asymmetric active EGFR dimer are phosphorylated differently. We monitored autophosphorylation in cells using flow cytometry and found that the first ∼80 residues of the tail are inhibitory, as demonstrated previously. The entire ∼80-residue span is important for autoinhibition and needs to be released from both kinases that form the dimer. These results are interpreted in terms of crystal structures of the inactive kinase domain, including two new ones presented here. Deletions in the remaining portion of the tail do not affect autophosphorylation, except for a six-residue segment spanning Tyr 1086 that is critical for activation loop phosphorylation. Phosphorylation of the two tails in the dimer is asymmetric, with the activator tail being phosphorylated somewhat more strongly. Unexpectedly, we found that reconstitution of the transmembrane and cytoplasmic domains of EGFR in vesicles leads to a peculiar phenomenon in which kinase domains appear to be trapped between stacks of lipid bilayers. This artifactual trapping of kinases between membranes enhances an intrinsic functional asymmetry in the two tails in a dimer.

25 June 2013 in BMC Biology
Verified
Journal Article
Open access
PDF file
SLSonja Lorenz
Sonja Lorenz
ACAaron J Cantor
Aaron J Cantor
MRMichael Rape
Michael Rape
JKJohn Kuriyan
John Kuriyan
The posttranslational modification of target proteins with ubiquitin and ubiquitin-like proteins is accomplished by the sequential action of E1, E2, and E3 enzymes. Members of the E1 and E3 enzyme families can undergo particularly large conformational changes during their catalytic cycles, involving the remodeling of domain interfaces. This enables the efficient, directed and regulated handover of ubiquitin from one carrier to the next one. We review some of these conformational transformations, as revealed by crystallographic studies.

19 May 2015 in Science Signaling
Verified
Journal Article
Open access
HSHanna Sjölin-Goodfellow
Hanna Sjölin-Goodfellow
MFMaria P. Frushicheva
Maria P. Frushicheva
QJQinqin Ji
Qinqin Ji
DCDebra A. Cheng
Debra A. Cheng
TKTheresa A. Kadlecek
Theresa A. Kadlecek
AWArthur Weiss
Arthur Weiss
The kinase ZAP-70 has both positive and negative functions in T cell signaling.